• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News & Analysis

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News & Analysis

Currency in USD Disclaimer

$246.98

-$1.81

(-0.73%)

Day's range
$245.32
Day's range
$250.68
50-day range
$229.86
Day's range
$304.39
  • Country: US
  • ISIN: US02043Q1076
52 wk range
$141.98
Day's range
$304.39
  • CEO: Dr. Yvonne L. Greenstreet M.B.A., MBChB
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 3.18
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ALNY)
  • Company Alnylam Pharmaceuticals, Inc.
  • Price $246.98
  • Changes Percentage (-0.73%)
  • Change -$1.81
  • Day Low $245.32
  • Day High $250.68
  • Year High $304.39

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/13/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $253.00
  • High Stock Price Target $400.00
  • Low Stock Price Target $96.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.65
  • Trailing P/E Ratio -57.65
  • Forward P/E Ratio -57.65
  • P/E Growth -57.65
  • Net Income $-440,242,000

Income Statement

Quarterly

Annual

Latest News of ALNY

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Alnylam Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of ALNY in the last quarter?

    In the last quarter Alnylam Pharmaceuticals, Inc. earnings were on Thursday, October, 31st. The Alnylam Pharmaceuticals, Inc. maker reported -$0.50 EPS for the quarter, beating analysts' consensus estimates of -$0.92 by $0.42.

  • What is the Alnylam Pharmaceuticals, Inc. stock price today?

    Today's price of Alnylam Pharmaceuticals, Inc. is $246.98 — it has decreased by -0.73% in the past 24 hours. Watch Alnylam Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Alnylam Pharmaceuticals, Inc. release reports?

    Yes, you can track Alnylam Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Alnylam Pharmaceuticals, Inc. stock forecast?

    Watch the Alnylam Pharmaceuticals, Inc. chart and read a more detailed Alnylam Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Alnylam Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Alnylam Pharmaceuticals, Inc. stock ticker.

  • How to buy Alnylam Pharmaceuticals, Inc. stocks?

    Like other stocks, ALNY shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Alnylam Pharmaceuticals, Inc.'s EBITDA?

    Alnylam Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Alnylam Pharmaceuticals, Inc.’s financial statements.

  • What is the Alnylam Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.2407941401, which equates to approximately -24.08%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Alnylam Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Alnylam Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Alnylam Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Alnylam Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Alnylam Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for Alnylam Pharmaceuticals, Inc. for its last quarter?

    Alnylam Pharmaceuticals, Inc. published it's last quarterly revenues at $500.92 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.